All In MedTech

Device Trial Radar · NCT03118037

Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry

Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE)

Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

182

Actual

Start

Jun 14, 2017

Primary completion

Nov 11, 2024

Study completion Nov 11, 2024

Sponsor

Lead sponsor
GynesonicsNot on our public-company list
Sponsor type
Industry
First posted
Apr 18, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SAGE is an observational post market registry with the objective of characterizing long term outcomes after treatment of uterine fibroids with the Sonata System in real world clinical practice settings.

Conditions

  • Uterine Fibroid

Interventions

  • Sonata SystemDevice

    Transcervical access for radiofrequency ablation of uterine fibroids

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Pregnancy and Pregnancy OutcomesTime frame: Up to 5 years-post procedure
  2. Surgical Re-intervention for Heavy Menstrual BleedingTime frame: Up to 5 years-post procedure

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Evangelisches Krankenhaus Köln-Weyertal gemeinnützige GmbH

    Cologne, Germany

  • Frauenklinik Universitätsklinikum Jena

    Jena, Germany

  • Klinik für Frauenheilkunde und Geburtshilfe

    Kempten, Germany

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.